Phenylketonuria and Metabolic Disease

Core Idea

Phenylketonuria (PKU) results from deficiency in phenylalanine hydroxylase, causing accumulation of phenylalanine and phenylpyruvate. High blood phenylalanine competitively inhibits tryptophan uptake, reducing serotonin synthesis and causing intellectual disability, light skin, and a musty odor. Early detection and dietary phenylalanine restriction prevent symptoms.

Explainer

From your study of aromatic amino acid catabolism, you know that phenylalanine is normally hydroxylated to tyrosine by phenylalanine hydroxylase (PAH), a reaction requiring the cofactor tetrahydrobiopterin (BH₄). This is the first committed step in phenylalanine degradation, and it is also the only metabolic route for disposing of excess phenylalanine. Phenylketonuria (PKU) is what happens when this single enzymatic step fails — and it illustrates a general principle of inborn errors of metabolism: when a pathway is blocked, the substrate accumulates and often enters alternative, normally minor routes that produce toxic byproducts.

In PKU, mutations in the PAH gene (or, less commonly, in BH₄ synthesis) reduce or eliminate hydroxylase activity. Phenylalanine accumulates in the blood to concentrations 10–50 times normal. Unable to proceed through its usual catabolic route, excess phenylalanine is transaminated to phenylpyruvate (the "phenylketone" that gives the disease its name), which is further reduced to phenyllactate and decarboxylated to phenylacetate. These compounds spill into the urine — phenylacetate is responsible for the characteristic musty or mousy odor of untreated PKU patients.

The neurological damage — intellectual disability, seizures, behavioral problems — is not caused directly by phenylpyruvate but by the high phenylalanine itself. Amino acid transport across the blood-brain barrier uses shared carriers, and phenylalanine competes with other large neutral amino acids, particularly tryptophan and tyrosine. When phenylalanine floods these transporters, tryptophan uptake into the brain drops, reducing serotonin synthesis. Tyrosine uptake also falls, impairing dopamine and melanin production — explaining why untreated PKU patients often have lighter skin, hair, and eyes than their unaffected siblings. The developing brain is especially vulnerable, which is why damage occurs primarily in infancy and childhood.

PKU is the textbook success story of newborn screening. The Guthrie test (a bacterial inhibition assay on a dried blood spot, now largely replaced by tandem mass spectrometry) detects elevated phenylalanine within days of birth, before any symptoms appear. Treatment is straightforward in concept — a low-phenylalanine diet that provides enough of this essential amino acid for growth but not so much that it accumulates — though maintaining the diet is demanding in practice, requiring lifelong restriction of high-protein foods and use of medical formula. Some patients with mild mutations respond to pharmacological doses of BH₄ (sapropterin), which stabilizes the mutant enzyme. PKU demonstrates that understanding the biochemistry of a metabolic block — what accumulates, what is depleted, and why — directly translates into rational therapy.